Bellerophon Therapeutics Creates PH-Focused Scientific Advisory Board For INOpulse Programs

Isaura Santos avatar

by Isaura Santos |

Share this article:

Share article via email

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, recently announced the formation of a Scientific Advisory Board (SAB) for its INOpulse technology that includes internationally recognized experts in the field of pulmonary hypertension (PH). The SAB will work closely with Bellerophon’s medical team while the firm prepares to further the advancement of its proprietary inhaled nitric oxide drug-device combination technology across a wide range of several indications for those affected by PH.

“Creation of the INOpulse Scientific Advisory Board underscores our commitment to the development of our technology in pulmonary hypertension for chronic outpatient use to benefit patients with various forms of this debilitating disease,” said Bellerophon’s CEO, Jonathan Peacock. “We are especially pleased to have such a distinguished group of thought leaders working with us to broaden and advance our programs in PH. The participation of these distinguished SAB members reflects the advances we have made in our clinical programs in the past year, and will help us define and advance our programs in the next few years.”

[adrotate group=”4″]

INOpulse is a nitric oxide drug-device combination technology, propriety of Bellerophon, that addresses drug delivery needs for pulmonary hypertension therapies in a chronic outpatient setting. The company has two programs currently in development that aim to treat PAH and are expected to be tested in Phase 3 trials this year; the firm has a second program to treat PH-COPD currently being evaluated for a Phase 2b trial.

[adrotate group=”3″]

Nitric oxide is released in the body to make muscles relax; it is also crucial to regulating blood pressure. Through relaxing muscles, blood flow increases, helping to deliver more blood to the body. Researchers at the firm expect that inhaled nitric oxide delivered through the INOpulse device can provoke relaxation of the airway muscles. Bellerophon owns exclusive rights to advance and market INOpulse to address PAH, PH-COPD and pulmonary hypertension (linked to idiopathic pulmonary fibrosis). Bellerophon is also assessing the potential of INOpulse to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and PH linked to Sarcoidosis.

Bellerophon Therapeutics is committed to developing new therapies with innovative drugs and devices that might address several unmet medical needs in the field of cardiac diseases.